塩酸ゲムシタビンの市場規模、シェア、成長分析：タイプ別、用途別、流通チャネル別、地域別 - 産業予測、2025～2032年

世界の塩酸ゲムシタビンの市場規模は、2023年に22億米ドルと評価され、2024年の23億3,000万米ドルから2032年には36億2,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは5.7％で成長する見通しです。

塩酸ゲムシタビンの世界市場は、特に膵臓がん、卵巣がん、肺がん、乳がんなどのがん罹患率の大幅な増加によって牽引されています。塩酸ゲムシタビンは様々な固形がんに対する化学療法レジメンの重要な構成要素として、がん治療に不可欠なものとなっています。人口の高齢化、ライフスタイルの変化、環境リスクなどの要因が、がん罹患率の上昇と効果的な治療法の需要に寄与しています。新興国では、診断率、ヘルスケアへのアクセス、化学療法の利用率が向上しており、市場の成長をさらに促進しています。ドラッグ製剤、リポソームデリバリーシステム、併用療法における技術革新は、医師による使用と患者の適格性を高めています。特許失効後のジェネリック医薬品の台頭は患者アクセスを拡大し、ヘルスケア支出の増大と個別化腫瘍学へのシフトは地域間の市場拡大を持続させると思われます。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の展望
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と展望

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ

塩酸ゲムシタビンの市場規模：タイプ別、CAGR（2025～2032年）

• 市場概要
• 先発品
• ジェネリック塩酸ゲムシタビン

塩酸ゲムシタビンの市場規模：用途別、CAGR（2025～2032年）

• 市場概要
• 膵臓がん
• 非小細胞肺がん
• 乳がん
• その他

塩酸ゲムシタビンの市場規模：流通チャネル別、CAGR（2025～2032年）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

塩酸ゲムシタビンの市場規模：地域別、CAGR（2025～2032年）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Eli Lilly and Company（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（USA）
• Mylan N.V.（USA）
• Fresenius Kabi AG（Germany）
• Accord Healthcare（United Kingdom）
• Sun Pharmaceutical Industries Ltd.（India）
• Dr. Reddy's Laboratories（India）
• Cipla Ltd.（India）
• Aurobindo Pharma（India）
• Sandoz International GmbH（Germany）

結論と提言

Global Gemcitabine Hydrochloride Market size was valued at USD 2.2 billion in 2023 and is poised to grow from USD 2.33 billion in 2024 to USD 3.62 billion by 2032, growing at a CAGR of 5.7% during the forecast period (2025-2032).

The global market for Gemcitabine Hydrochloride is being driven by a significant increase in cancer incidence, particularly in pancreatic, ovarian, lung, and breast cancers. As a vital component of chemotherapy regimens for various solid tumors, Gemcitabine Hydrochloride has become essential in oncology treatment. Factors like aging populations, lifestyle changes, and environmental risks contribute to rising cancer rates and demand for effective therapies. Emerging economies are witnessing improved diagnosis rates, healthcare access, and chemotherapy utilization, further promoting market growth. Innovations in drug formulations, liposomal delivery systems, and combination therapies are enhancing both physician use and patient eligibility. The advent of generics post-patent expirations has broadened patient access, while escalating healthcare expenditures and a shift towards personalized oncology are set to sustain market expansion across regions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gemcitabine Hydrochloride market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gemcitabine Hydrochloride Market Segments Analysis

Global Gemcitabine Hydrochloride Market is segmented by Type, Application, Distribution Channel and region. Based on Type, the market is segmented into Branded and Generic. Based on Application, the market is segmented into Pancreatic Cancer, Non-Small Cell Lung Cancer, Breast Cancer and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gemcitabine Hydrochloride Market

The increasing prevalence of cancer worldwide, particularly in cases such as pancreatic, lung, breast, and bladder cancers, significantly fuels the growth of the gemcitabine hydrochloride market. Its extensive efficacy and favorable safety profile have established gemcitabine hydrochloride as a fundamental component in cancer treatment regimens. Additionally, the ongoing research into new applications and the exploration of combination therapies involving gemcitabine further enhances its demand. As healthcare providers seek effective treatment solutions, the robust clinical interest surrounding this drug will likely contribute to sustained market progression, highlighting its vital role in oncology pharmacotherapy.

Restraints in the Global Gemcitabine Hydrochloride Market

The global market for gemcitabine hydrochloride faces significant constraints due to the expiration of patents on branded formulations, which has resulted in a surge of generic alternatives. This influx has intensified price competition, leading to reduced profitability for original manufacturers as they grapple with decreasing prices. While the availability of more competing products enhances accessibility for patients, it simultaneously places financial pressure on companies, potentially stifling innovation and investment in the development of new indications or improved delivery methods. As a result, these factors may hinder the growth and penetration of the gemcitabine hydrochloride market on a global scale.

Market Trends of the Global Gemcitabine Hydrochloride Market

The Global Gemcitabine Hydrochloride market is witnessing a significant trend towards the adoption of Artificial Intelligence (AI) in personalized chemotherapy. Key players are leveraging advanced AI and data analytics to enhance treatment planning, focusing on real-time patient monitoring and predictive modeling. This innovative approach aims to optimize individualized dosing plans, ensuring a more accurate and effective delivery of cancer treatment. As healthcare providers increasingly recognize the potential of AI to improve patient outcomes, the integration of these technologies in Gemcitabine Hydrochloride therapies is expected to drive market growth, transforming how cancer treatments are tailored to meet specific patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Gemcitabine Hydrochloride Market Size by Type & CAGR (2025-2032)

• Market Overview
• Branded
• Generic Gemcitabine Hydrochloride

Global Gemcitabine Hydrochloride Market Size by Application & CAGR (2025-2032)

• Market Overview
• Pancreatic Cancer
• Non-Small Cell Lung Cancer
• Breast Cancer
• Others

Global Gemcitabine Hydrochloride Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Gemcitabine Hydrochloride Market Size & CAGR (2025-2032)

• North America (Type, Application, Distribution Channel)
  • US
  • Canada
• Europe (Type, Application, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Accord Healthcare (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations